Loading...
XSHE300238
Market cap431mUSD
Jan 09, Last price  
11.94CNY
1D
-1.16%
1Q
0.59%
Jan 2017
-64.20%
IPO
18.16%
Name

Guanhao Biotech Co Ltd

Chart & Performance

D1W1MN
XSHE:300238 chart
P/E
102.11
P/S
7.83
EPS
0.12
Div Yield, %
0.00%
Shrs. gr., 5y
-0.81%
Rev. gr., 5y
-2.49%
Revenues
404m
+7.13%
22,375,47935,192,06065,569,016102,618,066128,510,115147,020,069168,501,935190,356,664226,172,526312,789,660450,366,981458,461,849437,886,453436,957,168488,981,886377,285,014404,178,697
Net income
31m
2,810,2427,094,82214,416,92132,341,05940,422,52037,031,45140,573,89450,103,14763,366,04256,955,82057,475,20445,746,533046,594,90073,687,006031,005,798
CFO
54m
-23.72%
04,802,7825,551,30333,755,38335,453,97949,124,92041,487,99565,448,67167,865,96230,680,82119,218,21532,276,11692,545,564103,839,533122,394,24370,983,73054,149,827
Dividend
Jun 20, 20180.05 CNY/sh
Earnings
Mar 26, 2025

Profile

Guanhao Biotech Co.,Ltd. develops, manufactures, and markets regenerative medicine in China. It offers NormalGEN, a type of biological dura repair patch manufactured from animal tissue; GrandNeuro, an artificial dura patch for dura repairing; ThormalGEN, a biological surgical patch manufactured from animal tissue for surgical repairs; DermalGEN, a wound dressing product manufactured from animal tissue for use on burns, scalds, and wounds due to skin loss or trauma; and IREAL breast patch. The company was founded in 1999 and is based in Guangzhou, China.
URL
http://www.guanhaobio.com/
IPO date
Jul 06, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
404,179
7.13%
377,285
-22.84%
Cost of revenue
258,581
317,709
Unusual Expense (Income)
NOPBT
145,598
59,576
NOPBT Margin
36.02%
15.79%
Operating Taxes
11,017
35,078
Tax Rate
7.57%
58.88%
NOPAT
134,581
24,498
Net income
31,006
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
24,519
56,541
Long-term debt
36,134
45,039
Deferred revenue
22,848
Other long-term liabilities
20,647
2
Net debt
(85,576)
(57,260)
Cash flow
Cash from operating activities
54,150
70,984
CAPEX
(53,919)
Cash from investing activities
(51,110)
Cash from financing activities
(27,324)
FCF
119,399
144,869
Balance
Cash
105,136
126,280
Long term investments
41,094
32,560
Excess cash
126,021
139,976
Stockholders' equity
(80,322)
296,539
Invested Capital
605,823
376,514
ROIC
27.40%
4.50%
ROCE
27.45%
11.42%
EV
Common stock shares outstanding
258,382
265,156
Price
13.57
32.00%
10.28
-44.52%
Market cap
3,506,239
28.63%
2,725,801
-44.52%
EV
3,420,663
2,668,541
EBITDA
174,604
92,619
EV/EBITDA
19.59
28.81
Interest
1,782
4,112
Interest/NOPBT
1.22%
6.90%